Esomeprazole
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Esomeprazole: Duodenal obstruction
One-Sentence Summary
Esomeprazole is a proton pump inhibitor (PPI) originally used for acid-related conditions such as peptic ulcer disease and gastroesophageal reflux disease. The TxGNN model predicts it may be useful for duodenal obstruction, but the evidence is thin: 0 clinical trials and 1 publication, a general review of PPIs that does not study this condition directly.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Duodenal obstruction |
| TxGNN Prediction Score | 0.9945 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs on record: at least 19; dormant: 1) |
| Number of DINs | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the data compiled for this report. Based on the known class mechanism, esomeprazole is a PPI. It blocks the H+/K+ ATPase (proton pump) in gastric parietal cells and so suppresses stomach acid. Its efficacy in acid-related disease is well established.
The high model score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 18679668 | 2008 | Review | European Journal of Clinical Pharmacology | Update on PPI clinical use and pharmacokinetics. PPIs are first-choice drugs for peptic ulcer, H. pylori infection, GERD, NSAID-related GI lesions and Zollinger-Ellison syndrome. It does not address duodenogastric reflux specifically. |
Canada Market Information
Esomeprazole has 20 valid single-ingredient authorizations in Canada and none are cancelled. Dosage form and approved indication text were not available for these entries. Five main products:
| DIN | Product Name | Status |
|---|---|---|
| 02244521 | NEXIUM - 20MG | Valid |
| 02244522 | NEXIUM - 40MG | Valid |
| 02300524 | NEXIUM | Valid |
| 02444712 | NEXIUM 24HR | Valid |
| 02339099 | APO-ESOMEPRAZOLE | Valid |
Safety Considerations
- Drug Interactions: 100 interactions were found. Major-level ones include acalabrutinib and atazanavir. Moderate-level ones include hydrochlorothiazide, atorvastatin, amphotericin B, amikacin, amphetamine, fenofibrate, apalutamide, armodafinil, bendamustine, bosutinib and bumetanide. Minor-level ones include acetylsalicylic acid, axitinib, bortezomib, brivaracetam and cyanocobalamin.
- Knowledge-graph contraindication signals (from a drug-disease network, not product label text): liver failure, osteoporosis, postmenopausal osteoporosis, bone fracture and chronic atrophic gastritis. These need verification against the official labelling.
Please refer to the package insert for the official warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but there are no clinical trials and only one general review, which does not study this condition. The mechanism is indirect: acid suppression does not treat bile reflux. The evidence is model prediction plus a general mechanistic argument, so I do not recommend advancing it now.
Another predicted indication in the same data, duodenal ulcer, has much stronger support: Phase 3 trials and RCTs. It is essentially already within esomeprazole’s established use, so it is not a true repurposing opportunity.
To proceed, the following is needed:
- Mechanism-of-action data
- Health Canada package insert warnings and contraindications
- Clinical studies of esomeprazole in duodenogastric (bile) reflux, ideally with symptom and mucosal-injury endpoints
- A comparison against therapies that target bile reflux itself
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.